Hemispherx BioPharma, Inc (HEB) Spikes On Extension Of Rintatolimod European EAP To Pancreatic Cancer

Shares of Hemispherx BioPharma, Inc (NYSEMKT:HEB) gained more than 12.75% in the last three days of the week, after the company announced its rintatolimod European early access...

Keep Reading →